Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company
29 open jobs
Associate Director, Clinical Operations (Contract)
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Associate Director, Clinical Operations (Contract) at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 7 days agoClinical Trial Manager (Contract)
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Clinical Trial Manager (Contract) at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 10 days agoSenior Scientist, Safety Assessment & Investigative Toxicology
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Senior Scientist, Safety Assessment & Investigative Toxicology at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 13 days agoAssociate Director, Study Operations Manager - Nonclinical Toxicology
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
(Associate) Director, Clinical Science
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto (Associate) Director, Clinical Science at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 14 days agoDirector, HEOR – Orexin Franchise
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Director, HEOR – Orexin Franchise at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 17 days agoSenior Clinical Trial Specialist (Contract)
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Senior Clinical Trial Specialist (Contract) at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 17 days agoSenior Clinical Trial Manager (Contract)
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Senior Clinical Trial Manager (Contract) at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 18 days agoAssociate Director, Clinical Quality Assurance
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Associate Director, Clinical Quality Assurance at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 19 days agoCMC Technical Writer (Contract)
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto CMC Technical Writer (Contract) at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 21 days agoSenior Director, Regulatory CMC
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Senior Director, Regulatory CMC at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 21 days agoAssociate Director, Regulatory Project Management
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Associate Director, Regulatory Project Management at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 21 days agoManager, Product Quality
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Manager, Product Quality at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 25 days agoSenior Advisor, Molecular Pharmacology
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Senior Advisor, Molecular Pharmacology at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 25 days agoSenior Director, DMPK Project Leader
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Senior Director, DMPK Project Leader at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 26 days agoManager, Clinical Supply Chain
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Manager, Clinical Supply Chain at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 26 days agoAssociate Director, Clinical Supply Chain
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Associate Director, Clinical Supply Chain at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 26 days agoDirector, Medicinal Chemistry
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Director, Medicinal Chemistry at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 26 days agoSenior Director, Global Medical Affairs
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Senior Director, Global Medical Affairs at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 26 days agoInventory Control Manager, Supply Chain (contractor)
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Inventory Control Manager, Supply Chain (contractor) at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 35 days agoDirector, External Quality Control & Stability
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Director, External Quality Control & Stability at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 39 days agoSenior Advisor, Regulatory Starting Material
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Senior Advisor, Regulatory Starting Material at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 46 days agoSenior Advisor, Manufacturing Package Design
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Senior Advisor, Manufacturing Package Design at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 46 days agoSenior Director, Analytical Development CMC
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Senior Director, Analytical Development CMC at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 48 days agoSenior Director, Drug Product CMC
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Senior Director, Drug Product CMC at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 48 days agoAssociate Project Manager, Drug Development
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Associate Project Manager, Drug Development at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 48 days agoAssociate Director, Project Management
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Associate Director, Project Management at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 48 days agoMedical Science Liaison (MSL) – South East
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Medical Science Liaison (MSL) – South East at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 83 days agoMedical Science Liaison (MSL) – North Central
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead
Applyto Medical Science Liaison (MSL) – North Central at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company seen live 1 day ago posted 83 days ago